What is ADP adoptive cell therapy studying for neoplasms?

ADP adoptive cell therapy is being studied to assess its long-term safety in people who have received this treatment for neoplasms. This study follows participants for up to 15 years after their last therapy infusion to monitor any delayed effects. It is sponsored by USWM CT, LLC and aims to provide important safety information over time.

Who may be eligible for this neoplasm clinical trial?

Adults who have received at least one dose of ADP adoptive cell therapy and who have completed or withdrawn from related studies may be eligible. Both men and women can participate if they can give informed consent and follow local contraceptive guidelines. Please review eligibility criteria for more details.

Is there any cost to participate in this neoplasm clinical trial?

Study-related care, including all trial visits and monitoring, is provided at no cost. However, personal travel expenses and other costs may vary and are not guaranteed to be covered. Participants should plan accordingly for any additional expenses.

Actively Recruiting

Phase 1

All Genders

ID03391778

Long-Term Follow-Up LTFU of Participants Treated With ADP Adoptive Cell Therapies

Led by USWM CT, LLC · Updated on 2026-03-03

250

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

This research aims to evaluate the long-term safety of individuals who have received ADP adoptive cell therapy, a type of biological treatment, for cancers neoplasms. This non-therapeutic, multi-center study will follow participants for up to 15 years after their last infusion of this lentiviral vector-based adoptive cell therapy. The focus is on monitoring safety over an extended period, reflecting the importance of understanding long-term effects after such treatments. Participants in this study have previously received at least one dose of ADP adoptive cell therapy during earlier trials or through managed access programs supported by GSK. No additional study drug is given during this follow-up study. Instead, participants will be observed and evaluated to track any delayed adverse events or changes related to the therapy they received. The study does not involve randomization or masking and includes only those who have completed or withdrawn from prior ADP-related studies. During the study, participants will undergo regular monitoring, including blood sample tests to detect specific DNA copies and vector integration patterns related to the therapy. Researchers will record any serious or delayed adverse events, deaths, and time to death over the 15-year follow-up period. The study involves signing informed consent and requires participants to follow local contraceptive guidelines. Participant involvement includes long-term safety assessments but does not involve new treatment administration.

CONDITIONS

Brief Title

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Who Can Participate

All Genders

Eligibility Criteria

You may qualify if you...

Participants who have received at least one dose of ADP adoptive cell therapy agent.
Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
The investigator is responsible for review of medical history.
Capable of giving signed informed consent.

You will not qualify if you...

None

Research Team

Investigator Study Inquiries LTFU

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here